{"nctId":"NCT01461824","briefTitle":"Drug Exposure and Depot Medroxyprogesterone Acetate (DMPA) in Adolescent Subjects","startDateStruct":{"date":"2011-09"},"conditions":["Weight Gain","Disorder of Bone Density and Structure, Unspecified","Uterine Bleeding"],"count":34,"armGroups":[{"label":"150 mg DMPA","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Depot medroxyprogesterone acetate (DMPA)"]},{"label":"104mg DMPA","type":"EXPERIMENTAL","interventionNames":["Drug: Depot medroxyprogesterone acetate (DMPA)"]},{"label":"75mg DMPA","type":"EXPERIMENTAL","interventionNames":["Drug: Depot medroxyprogesterone acetate (DMPA)"]}],"interventions":[{"name":"Depot medroxyprogesterone acetate (DMPA)","otherNames":["Generic Depo Provera manufactured by Greenstone, LLC"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Age 12-21 years\n2. Healthy, post-menarcheal female\n3. Self-selected to initiate depot medroxyprogesterone acetate (DMPA)\n4. Willingness to use a barrier method of contraception in addition to DMPA\n\nExclusion Criteria:\n\n1. Chronic disease known to affect weight or bone mineral density (BMD) (e.g. diabetes, kidney)\n2. Use of medication known to affect weight or BMD (e.g. corticosteroids)\n3. DMPA use within the past 12 months\n4. Pregnancy within the past 6 months\n5. Etonogestrel implant, levonorgestrel-releasing intrauterine system or combined estrogen/progesterone contraceptive use within the past 30 days (OC, patch, vaginal ring)\n6. Weight exceeding 450 lbs\n7. Need for confidential contraceptive care for individuals \\< 18 years of age.","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"12 Years","maximumAge":"21 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change in Lumbar Spine Bone Mineral Density (BMD) From Baseline to 48 Weeks","description":"Lumbar spine bone mineral density measured at baseline and 48 weeks. Percent change over this time was calculated.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.0","spread":"2.76"},{"groupId":"OG001","value":"-3.1","spread":"1.84"},{"groupId":"OG002","value":"-0.6","spread":"5.91"}]}]}]},{"type":"PRIMARY","title":"Proportion of Participants With >5% Weight Gain at 24 Weeks","description":"Individual subjects will be assessed after their Week 24 visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change in Total Hip BMD From Baseline to 48 Weeks","description":"Total hip bone mineral density was assessed at baseline and 48 weeks. Percent change from baseline to 48 weeks was calculated.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.0","spread":"3.22"},{"groupId":"OG001","value":"-1.6","spread":"2.53"},{"groupId":"OG002","value":"-0.1","spread":"5.07"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":12},"commonTop":["Upper respiratory infection","Headache","Uterine pain","Irregular menstruation","Sore throat"]}}}